Skip to main content
Premium Trial:

Request an Annual Quote

BioSeek to Collaborate with Ono

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Predictive biology company BioSeek said today that it will collaborate with Ono Pharmaceutical in a drug target screening collaboration.

Under a three-year agreement, BioSeek will use its BioMap platform in a collaboration that will focus on a specific drug target class designated by Ono.

BioSeek will use the Biomap to perform phenotypic screening and hit identification, lead optimization, and clinical candidate selection. For its efforts, BioSeek, which is a subsidiary of Asterand, will receive research funding and a milestone payment linked to development of the Ono drug candidate.

Osaka, Japan-based Ono will have the worldwide rights to develop and sell any pharmaceutical products discovered through the collaboration.

The BioMap systems use cell-based models of pathway interactions to understand toxicological properties of compounds including target effects, dose responses, and the discrimination of related compounds.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.